Chest - McMaster Experts

publication venue for

Noninvasive Oxygenation Strategies in Adult Patients With Acute Hypoxemic Respiratory Failure 2023
Observation, Aspiration, or Tube Thoracostomy for Primary Spontaneous Pneumothorax 2023
Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia 2023
MALIGNANT TRANSFORMATION OF A SOLITARY TRACHEAL PAPILLOMA IN THE ABSENCE OF HUMAN PAPILLOMAVIRUS INFECTION IN A PATIENT WITH 48, XYYY SYNDROME: CASE REPORT 2022
Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease 2022
Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease 2022
Effects of Traffic-Related Air Pollution on Exercise Endurance, Dyspnea, and Cardiorespiratory Responses in Health and COPD 2022
Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2021
ENDOBRONCHIAL ULTRASOUND STAGING OF OPERABLE NSCLC: TRIPLE NEGATIVE LYMPH NODES MAY NOT REQUIRE ROUTINE BIOPSY 2019
EXTRACORPOREAL LIVER SUPPORT IN PATIENTS WITH ACUTE OR ACUTE ON CHRONIC LIVER FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS 2019
ENHANCING PULMONARY REHABILITATION ENROLMENT STUDY (PRESS III) 2018
POWER: Prospective Cohort Study for the Real-Life Effectiveness Evaluation of Glycopyrronium With Indacaterol Combination in the Management of COPD in Canada 2016
Pleural Solitary Fibrous Stromal Tumor: Beware of the Elevated Hemidiaphragm 2016
Community-Acquired Pneumonia in Older and Younger Adults With Diabetes Mellitus 2015
GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence Study 2015
Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study 2015
Physiologic Characterization of the Chronic Bronchitis Phenotype in GOLD Grade IB COPD 2015
Evaluation of a Novel Method of Teaching Endobronchial Ultrasound: Interventional Pulmonologist Versus Respiratory Therapist Proctored Simulation Training 2013
Intracavitary Pulmonary Aspergilloma Removal Using Combined Virtual, Ultrathin, and Rigid Bronchoscopy - A Case Series 2013
Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease 2013
Weaning Dobutamine in a Patient With Severe Cardiogenic Shock Using Hemodynamic Transesophageal Echocardiography 2013
A SINGLE DOSE OF MEDI-528, A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-9, IS WELL TOLERATED IN MILD AND MODERATE ASTHMATICS IN THE PHASE II TRIAL MI-CP-138 2007
A RANDOMIZED TRIAL OF STRATEGIES FOR ASSESSING ELIGIBILITY FOR LONG-TERM DOMICILIARY OXYGEN THERAPY 2005
Do restrictive reimbursement processes inhibit physicians from adopting and implementing guidelines into their practice: The Canadian asthma experience 2005
FACTORS AFFECTING SUCCESSFUL TRANSITION FROM HIGH FREQUENCY OSCILLATION TO CONVENTIONAL MECHANICAL VENTILATION IN ADULT PATIENTS 2005
LUNG DEPOSITION OF QVAR (HFA134A-BDP) IN NEWBORN INFANTS WITH BRONCHOPULMONARY DYSPLASIA (BPD) 2005
RESISTANCE PHENOTYPES OF STREPTOCOCCUS PNEUMONIAE AND CLINICAL OUTCOME OF RESPIRATORY TRACT INFECTIONS TREATED WITH GEMIFLOXACIN 2005
RISK PROFILES AND PROPHYLAXIS HISTORY OF PATIENTS DEVELOPING VENOUS THROMBOEMBOLISM IN THE OUTPATIENT SETTING: THE WORCESTER VENOUS THROMBOEMBOLISM STUDY 2005
THE CHANGING LANDSCAPE OF VENOUS THROMBOEMBOLISM: THE WORCESTER VENOUS THROMBOEMBOLISM STUDY 2005
The 2005 asthma action study in Canada 2005
An overview of the efficacy of gemifloxacin for the treatment of community-acquired pneumonia (CAP) 2004
Early vs delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: A clinical endpoint study 2004
Improved Aerosolization of Suspensions Using Electronic Micropump Technology Compared to Conventional Pneumatic Nebulization 2004
Safety and Efficacy of Gemifloxacin Compared to High Dose Amoxicillin/Clavulanate for the Treatment of Community-Acquired Pneumonia (CAP) of Suspected Pneumococcal Origin 2004
Safety and Tolerability of Gemifloxacin: A Review of Clinical Trial Data 2004
The Efficacy of 5-Day Gemifloxacin Once Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis (AECB) 2004
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction 2004
Airway Hyperresponsiveness 2003
Adenovirus-Mediated Gene Transfer of the Proteoglycan Biglycan Induces Fibroblastic Responses in the Lung 1997
In Vivo Adenovirus-Mediated Expression of Human Pre-Elafin, a Potent Neutrophil Elastase Inhibitor 1997
From the Bench to the Bedside: The Future of Sepsis Research 1997
The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma 1997
ANTITHROMBOTIC THERAPY IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY 1995
Aspirin and Other Platelet-Active Drugs 1995
Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism 1995
NEW ANTITHROMBOTICS 1995
Use of Antithrombotic Agents During Pregnancy 1995
MORTALITY AMONG WORKERS WITH SILICOSIS IN ONTARIO 1987
Lung Cancer in a Steel Foundry 1986
TREATMENT OF OBSTRUCTIVE SLEEP-APNEA BY DIFFERENTIAL SUPRAHYOID MUSCLE REPOSITIONING 1985
A PROSPECTIVE-STUDY OF VENTILATION-PERFUSION LUNG-SCANNING AND PULMONARY ANGIOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM 1982
LUNG EPITHELIAL PERMEABILITY IN NORMAL SUBJECTS, ASTHMATICS AND SMOKERS 1982
Sputum Cellularity and MRI Ventilation Defects in Severe Asthma.. S0012-3692(25)00648-8. 2025
XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma. S0012-3692(25)00441-6. 2025
Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.. 167:477-489. 2025
Long-Term Mental Health Morbidity in Adult Survivors of COVID-19 Critical Illness: A Population-Based Cohort Study.. 167:S0012-3692(25)00105-9. 2025
BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease.. 167:172-182. 2025
Plasminogen: The Not-as-Obvious But Obvious Choice for Lytic Therapy.. 167:6-8. 2025
DESIGN OF THE LANDMARK CALM-1 AND CALM-2 PHASE 3 CLINICAL TRIALS OF CAMLIPIXANT IN REFRACTORY CHRONIC COUGH. 166:97A-99A. 2024
Lung Ultrasound in the ED: Will Death Do Us Part?. 166:418-419. 2024
Use of Intravenous Albumin. 166:321-338. 2024
Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis. 165:1435-1443. 2024
CT Airway Mucus in Older People Without Chronic Respiratory Illness. 166:429-432. 2024
The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease. 166:517-527. 2024
Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. 164:1466-1475. 2023
EFFECTIVENESS OF BENRALIZUMAB AFTER 12 MONTHS OF TREATMENT IN CANADIANS WITH SEVERE ASTHMA. 164:4898A-4900A. 2023
Fluid Therapy in Sepsis. 164:812-813. 2023
Epinephrine in Out-of-Hospital Cardiac Arrest. 164:381-393. 2023
Perioperative Management of Vitamin K Antagonists and Direct Oral Anticoagulants. 163:1245-1257. 2023
Outpatient Mental Health Follow-up and Recurrent Self-harm and Suicide Among Patients Admitted to the ICU for Self-harm. 163:815-825. 2023
Critical Care Transesophageal Echocardiography for the Resuscitation of Shock. 163:268-269. 2023
Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. 163:345-357. 2023
Corticosteroids in Community-Acquired Pneumonia. 163:e47-e48. 2023
COVID-19. 162:1297-1305. 2022
Executive Summary. 162:1127-1139. 2022
Perioperative Management of Antithrombotic Therapy. 162:e207-e243. 2022
Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose. 162:520-533. 2022
Implications of the COVID-19 Pandemic for the Well-Being of the ICU Workforce Considerations for the ICU Interprofessional Team. 162:285-287. 2022
A 68-Year-Old Woman With Refractory Cough and Insidious Tracheal Thickening. 161:e287-e291. 2022
Complications of Critical COVID-19. 161:989-998. 2022
Detection and Early Referral of Patients With Interstitial Lung Abnormalities. 161:470-482. 2022
VTE Prophylaxis in Critically Ill Adults. 161:418-428. 2022
Persistent Exertional Intolerance After COVID-19. 161:54-63. 2022
The Usefulness of the Rapid Shallow Breathing Index in Predicting Successful Extubation. 161:97-111. 2022
Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. 160:2158-2162. 2021
Caution When Comparing the Impact of Corticosteroids in COVID-19. 160:e243-e244. 2021
Risk Perception Among a Lung Cancer Screening Population. 160:718-730. 2021
The Burden of Mental Illness Among Survivors of Critical Care—Risk Factors and Impact on Quality of Life. 160:157-164. 2021
Endobronchial Ultrasound Staging of Operable Non-small Cell Lung Cancer. 159:2470-2476. 2021
Safety and Efficacy of Dexmedetomidine in Acutely Ill Adults Requiring Noninvasive Ventilation. 159:2274-2288. 2021
Response. 159:2115-2115. 2021
Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation. 159:e181-e184. 2021
Dosing Fluids in Early Septic Shock. 159:1493-1502. 2021
Response. 159:1301-1302. 2021
Lung-Protective Ventilation and Associated Outcomes and Costs Among Patients Receiving Invasive Mechanical Ventilation in the ED. 159:606-618. 2021
A Tool to Assess Participation in People With COPD. 159:138-146. 2021
POINT: Should Corticosteroids Be Routine Treatment in Early ARDS? Yes. 159:25-29. 2021
Rebuttal From Drs Meduri and Rochwerg. 159:35-37. 2021
Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. 158:2270-2274. 2020
High-Flow Nasal Cannula in the Immediate Postoperative Period. 158:1934-1946. 2020
Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma. 158:1350-1360. 2020
Key Highlights of the Canadian Thoracic Society’s Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic. 158:869-872. 2020
Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. 158:1069-1078. 2020
Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. 158:479-490. 2020
Luminal Eosinophil Cell Death as a Biomarker for Loss of Asthma Control?. 157:1680-1681. 2020
Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease. 157:1207-1220. 2020
The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough. 157:111-118. 2020
Nonidentical Twins With Asthma. 156:e111-e116. 2019
Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. 156:887-895. 2019
Response. 156:808-809. 2019
Determinants of Depressive Symptoms at 1 Year Following ICU Discharge in Survivors of ≥ 7 Days of Mechanical Ventilation. 156:466-476. 2019
CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma. 155:1178-1189. 2019
The Aging Lung. 155:391-400. 2019
Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. 155:69-78. 2019
Spread the Word About CHEST in 2019. 155:1-4. 2019
Antimicrobial Resistance and Respiratory Infections. 154:1202-1212. 2018
Expiratory Flow Limitation During Mechanical Ventilation. 154:948-962. 2018
Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team. 154:309-316. 2018
Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. 153:1396-1404. 2018
The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD. 153:1134-1141. 2018
Giants in Chest Medicine. 153:776-777. 2018
IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia. 152:453-455. 2017
Hematopoietic Processes in Eosinophilic Asthma. 152:410-416. 2017
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. 152:81-91. 2017
Epithelial-Derived Cytokines in Asthma. 151:1338-1344. 2017
The Potential Role of Aspiration in the Asthmatic Airway. 151:1272-1278. 2017
An Update on Lymphocyte Subtypes in Asthma and Airway Disease. 151:1122-1130. 2017
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. 151:127-138. 2017
POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes. 151:14-17. 2017
Rebuttal From Dr O’Byrne. 151:20-21. 2017
Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. 150:1015-1022. 2016
Measuring Eosinophils to Make Treatment Decisions in Asthma. 150:485-487. 2016
Platelet Activation Testing for Heparin-Induced Thrombocytopenia Antibodies. 150:478-480. 2016
Objective Cough Frequency, Airway Inflammation, and Disease Control in Asthma. 149:1460-1466. 2016
Surfactant Protein-D and Asthma. 149:1121-1122. 2016
Interpretability of Change Scores in Measures of Balance in People With COPD. 149:696-703. 2016
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. 149:315-352. 2016
Platelet Transfusion Practices in the ICU: Data From a Large Transfusion Registry. 150:516-523. 2016
Correction to Dosage in: Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis: 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 148:1529-1529. 2015
Table in: Dosing Frequency of Unfractionated Heparin Thromboprophylaxis: A Meta-analysis (vol 140, pg 374, 2011). 148:1363-1363. 2015
Timing the First Postoperative Dose of Anticoagulants. 148:587-595. 2015
Distractive Auditory Stimuli in the Form of Music in Individuals With COPD. 148:417-429. 2015
The Role for Optical Density in Heparin-Induced Thrombocytopenia. 148:55-61. 2015
Pain and Its Clinical Associations in Individuals With COPD. 147:1246-1258. 2015
Physiologic Characterization of the Chronic Bronchitis Phenotype in GOLD Grade IB COPD. 147:1235-1245. 2015
Hospitalized Exacerbations of COPD. 147:999-1007. 2015
Family-Based Psychosocial Support and Education as Part of Pulmonary Rehabilitation in COPD. 147:662-672. 2015
Is Quadriceps Endurance Reduced in COPD?. 147:673-684. 2015
Self-Management Following an Acute Exacerbation of COPD. 147:646-661. 2015
The Effect of Omega-3 Fatty Acids on Bronchial Hyperresponsiveness, Sputum Eosinophilia, and Mast Cell Mediators in Asthma. 147:397-405. 2015
Development of a novel, multilayered presentation format for clinical practice guidelines. 147:754-763. 2015
Spread the Word About CHEST in 2015. 147:1-3. 2015
New Approaches to TB Vaccination. 146:804-812. 2014
Risk of Mycobacterial Infections Associated With Rheumatoid Arthritis in Ontario, Canada. 146:563-572. 2014
Do Field Walking Tests Produce Similar Cardiopulmonary Demands to an Incremental Treadmill Test in Obese Individuals With Treated OSA?. 146:81-87. 2014
A Man in His 40s With Fever and Hypotension. 145:e17-e19. 2014
Measurement Properties of the Incremental Shuttle Walk Test. 145:1357-1369. 2014
Non-Vitamin K Antagonist Oral Anticoagulants. 145:1177-1178. 2014
Response. 145:1174-1175. 2014
Measurement of Activities of Daily Living in Patients With COPD. 145:253-271. 2014
Trends in the Prevalence of Asthma. 145:219-225. 2014
Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process. 146:727-734. 2014
Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the antithrombotic therapy and the prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 146:735-761. 2014
A Randomized Controlled Trial of Balance Training During Pulmonary Rehabilitation for Individuals With COPD. 144:1803-1810. 2013
Airways Disease Presenting as Restrictive Impairment: Response. 144:1979-1980. 2013
Perioperative Management of Antiplatelet Therapy in Patients With a Coronary Stent Who Need Noncardiac Surgery. 144:1848-1856. 2013
Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. 144:1222-1229. 2013
Improving Clinical Interpretation of the Anti-Platelet Factor 4/Heparin Enzyme-Linked Immunosorbent Assay for the Diagnosis of Heparin-Induced Thrombocytopenia Through the Use of Receiver Operating Characteristic Analysis, Stratum-Specific Likelihood Ratios, and Bayes Theorem. 144:1269-1275. 2013
Interruption of Warfarin Anticoagulation for Dental Surgery: Response. 144:1424-1426. 2013
Population-Based Risk of Mycobacterial Infections Associated With Anti-Tumor Necrosis Factor (anti-TNF) Therapy in Older Patients in Ontario, Canada. 144:270a-270b. 2013
Systematic Review of Supervised Exercise Programs After Pulmonary Rehabilitation in Individuals With COPD. 144:1124-1133. 2013
Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis. 144:1207-1215. 2013
Variation in Diagnostic Testing in Intensive Care Units: A Comparison of Teaching and Nonteaching Hospitals in a Regional System. 144. 2013
Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. 144:848-858. 2013
Creating Clinical Practice Guidelines. 144:365-367. 2013
Detection of COPD Exacerbations and Compliance With Patient-Reported Daily Symptom Diaries Using a Smartphone-Based Information System. 144:507-514. 2013
Arm Elevation and Coordinated Breathing Strategies in Patients With COPD. 144:128-135. 2013
The Occurrence and Impact of Bacterial Organisms Complicating Critical Care Illness Associated With 2009 Influenza A(H1N1) Infection. 144:39-47. 2013
American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. 143:1191-1191. 2013
Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease. 143:1098-1105. 2013
Are Asymptomatic DVTs Relevant? One Measure for All Response. 143:874-875. 2013
Asthma Associated With Incontinentia Pigmenti and Fanconi Anemia. 143:856-858. 2013
The Poorly Explored Impact of Uncontrolled Asthma. 143:511-523. 2013
Are Asymptomatic DVTs Relevant?: Response. 143:874-875. 2013
Creating clinical practice guidelines we can trust, use, and share: a new era is imminent. 144:381-389. 2013
Experiences with a novel policy for managing conflicts of interest of guideline developers: a descriptive qualitative study. 144:398-404. 2013
Low anonymous voting compliance with the novel policy for managing conflicts of interest implemented in the 9th version of the American College of Chest Physicians antithrombotic guidelines. 144:1111-1116. 2013
The Influence of Cigarette Smoking on Viral Infections. 143:196-206. 2013
Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg 7S, 2012). 142:1698-1698. 2012
The Pros and Cons of Propensity Scores. 142:1380-1382. 2012
Heparin-Induced Thrombocytopenia in the ICU. 142:815-816. 2012
Role of Cystic Fibrosis Transmembrane Conductance Regulator in Patients With Chronic Sinopulmonary Disease. 142:996-1004. 2012
Safety and Feasibility of Femoral Catheters During Physical Rehabilitation in the ICU. 142:365A-365A. 2012
Pulmonary Rehabilitation. 142:738-749. 2012
Angiogenesis in Pulmonary Fibrosis. 142:200-207. 2012
Impairments in Systems Underlying Control of Balance in COPD. 141:1496-1503. 2012
Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg 7S, 2012). 141:1129-1129. 2012
Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg e326S, 2012). 141:1129-1129. 2012
Mine Is Bigger Than Yours. 141:595-598. 2012
Antiplatelet Drugs. 141:e89S-e119S. 2012
Antithrombotic Therapy for Atrial Fibrillation. 141:e531S-e575S. 2012
Antithrombotic Therapy in Neonates and Children. 141:e737S-e801S. 2012
Defining the Relationship Between Average Daily Energy Expenditure and Field-Based Walking Tests and Aerobic Reserve in COPD. 141:406-412. 2012
Diagnosis of DVT. 141:e351S-e418S. 2012
Evidence-Based Management of Anticoagulant Therapy. 141:e152S-e184S. 2012
New Antithrombotic Drugs. 141:e120S-e151S. 2012
Oral Anticoagulant Therapy. 141:e44S-e88S. 2012
Parenteral Anticoagulants. 141:e24S-e43S. 2012
Perioperative Management of Antithrombotic Therapy. 141:e326S-e350S. 2012
Prevention of VTE in Orthopedic Surgery Patients. 141:e278S-e325S. 2012
Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma. 141:513-514. 2012
The Effect of Pulmonary Rehabilitation on Critical Walk Speed in Patients With COPD. 141:413-419. 2012
Treatment and Prevention of Heparin-Induced Thrombocytopenia. 141:e495S-e530S. 2012
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy. 141:e691S-e736S. 2012
American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:7S-47S. 2012
American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:e419S-94S. 2012
Antithrombotic and thrombolytic therapy for ischemic stroke.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:e601S-e636S. 2012
Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:e601S-e636S. 2012
Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:e419S-94S. 2012
Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:e419S-e496S. 2012
Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:e669S-e690S. 2012
Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:e185S-e194S. 2012
Clarification of Once-Daily Low-Molecular-Weight Heparin Dosing in Pulmonary Embolism: Response. 142:1075-1076. 2012
Do CIs Give You Confidence?. 141:17-19. 2012
Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:7S-7S. 2012
How Should We Measure Arm Exercise Capacity in Patients With COPD?. 141:111-120. 2012
Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:48S-52S. 2012
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:53S-70S. 2012
Panel List. 141:3S-3S. 2012
Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141:e1S-e23S. 2012
Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. 141:308-320. 2012
Preventing VTE in Outpatients With Cancer: Response. 142:266-267. 2012
Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:e195S-e226S. 2012
Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. 141:e637S-e668S. 2012
Serum Procalcitonin and Infective Exacerbations of Asthma. 140:1389-1390. 2011
A Prospective Quality Assurance Study of Proper Utilization of Metered-Dose Inhalers in the Medical Inpatient Population. 140:1025a. 2011
Evidence Incorporating Patients' Values: Response. 140:832-833. 2011
Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. 140:706-714. 2011
Properties of Self-Paced Walking in Chronic Respiratory Disease. 140:737-743. 2011
Dosing Frequency of Unfractionated Heparin Thromboprophylaxis. 140:374-381. 2011
Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. 140:366-373. 2011
Correction for Multiple Testing. 140:16-18. 2011
Early Postoperative Pulmonary Vascular Compliance Predicts Outcome After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. 140:34-41. 2011
Point: Is Measuring Sputum Eosinophils Useful in the Management of Severe Asthma? Yes. 139:1270-1273. 2011
Rebuttal From Drs Hargreave and Nair. 139:1275-1277. 2011
Assessing the Performance of the HAS-BLED Score: Response. 139:1248-1248. 2011
Simulator Training for Recognition of Murmurs. 139:1257-1258. 2011
The HAS-BLED Score and Renal Failure: Response. 139:1249-1250. 2011
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) (vol 133, pg 340S, 2008). 139:1261-1261. 2011
Nontubercular Mycobacterial Pulmonary Infection in Severe Asthma. 139:721-721. 2011
Alternative Therapy. 139:475-476. 2011
Comparison of the Effect of Low-Dose Ciclesonide and Fixed-Dose Fluticasone Propionate and Salmeterol Combination on Long-term Asthma Control. 139:311-318. 2011
The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness. 139:271-278. 2011
Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. 139:764-774. 2011
Factors at Admission Associated With Bleeding Risk in Medical Patients. 139:69-79. 2011
More Rigor Needed in Systematic Reviews on “Waterpipe”(Hookah, Narghile, Shisha) Smoking: Response. 139:1251-1252. 2011
Resistance Arm Training in Patients With COPD. 139:151-158. 2011
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. 138:1093-1100. 2010
Benefit of Roflumilast Therapy Added to Salmeterol in Patients With Varying Chronic Obstructive Pulmonary Disease Severity. 138:467A-467A. 2010
CHA 2 DS 2 -VASc Risk Scheme: Response. 138:1020-1021. 2010
Efficacy of Roflumilast in Chronic Obstructive Pulmonary Disease Patients With or Without Inhaled Corticosteroid Pretreatment. 138:464A-464A. 2010
Safety of Uninterrupted Anticoagulation in Patients Requiring Elective Coronary Angiography With or Without Percutaneous Coronary Intervention. 138:840-847. 2010
The 4T and Chong Scores Correlate With Outcomes for Heparin-Induced Thrombocytopenia. 138:188A-188A. 2010
Conclusion. 138:44S-45S. 2010
Introduction. 138:1S-3S. 2010
Measuring Bronchitis in Airway Diseases: Clinical Implementation and Application. 138:38S-43S. 2010
Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response. 138:239-240. 2010
A Comparison of Obese and Nonobese People With Asthma. 137:1316-1323. 2010
Recent Advances in the Pathophysiology of Asthma. 137:1417-1426. 2010
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. 137:263-272. 2010
Deep Vein Thrombosis Prophylaxis: Response. 136:1700-1701. 2009
Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism. 136:1537-1545. 2009
The Effects of Inhaled Budesonide on Lung Function in Smokers and Nonsmokers With Mild Persistent Asthma. 136:1514-1520. 2009
Changes in Exhaled Nitric Oxide Related to Estrogen and Progesterone During the Menstrual Cycle. 136:1301-1307. 2009
ADDITIONAL CLINICAL BENEFIT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATED WITH ROFLUMILAST AND SALMETEROL. 136:3s-f1-3s-f2. 2009
Medical Questionnaires Are Copyrighted To Ensure That Validity Is Maintained. 136:951-952. 2009
THE PROFILE OF CHRONIC OBSTRUCTIVE DISEASE IN THE PRIMARY CARE SETTING. 136:87S-87S. 2009
Safety of Long-Acting β-Agonists. 136:604-607. 2009
Antiinflammatory Effects of Long-Acting β 2 -Agonists in Patients With Asthma. 136:145-154. 2009
Balancing the Risks and Benefits of Thromboprophylaxis in Patients Undergoing Podiatric Surgery. 135:888-890. 2009
The American College of Chest Physicians Evidence-Based Educational Guidelines for Continuing Medical Education Interventions. 135:834-837. 2009
Variations and Gaps in Management of Acute Asthma in Ontario Emergency Departments. 135:724-736. 2009
American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. 135:513-520. 2009
D-dimer in patients with clinically suspected pulmonary embolism. 1993.. 136. 2009
The Need for Expertise and the Scientific Base of Evidence-Based Medicine: Response. 135:245-246. 2009
Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β 2 -Agonists in Achieving Asthma Control. 134:1192-1199. 2008
Eosinophil Progenitors in Airway Diseases. 134:1037-1043. 2008
Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial). 134:794-800. 2008
Rapid Effect of Inhaled Ciclesonide in Asthma. 134:740-745. 2008
THE EFFECT OF ALLERGEN SELECTION ON AIRWAY RESPONSES AFTER ALLERGEN CHALLENGE USED FOR THE EVALUATION OF DRUG THERAPY IN ASTHMA. 134:6P-6P. 2008
Asthma Management by Monitoring Sputum Neutrophil Count. 134:628-630. 2008
Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition) (Chest (June 2008) 133 SUPPL (110S-112S)). 134:473. 2008
Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (vol 133, pg 110S, 2008). 134:473-473. 2008
Grades of recommendation for antithrombotic agents (vol 133, pg 123S, 2008). 134:473-473. 2008
Methodology of antithrombotic and thrombolytic therapy guideline development (vol 133, pg 133S, 2008). 134:473-473. 2008
New antithrombotic drugs (vol 133, pg 234S, 2008). 134:473-473. 2008
Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition) (vol 133, pg 141S, 2008). 134:474-474. 2008
What Is the Burden of Chronic Cough for Families?. 134:303-309. 2008
Antiplatelet Drugs. 133:199S-233S. 2008
Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes. 133:670S-707S. 2008
Antithrombotic Therapy in Neonates and Children. 133:887S-968S. 2008
Antithrombotic and Thrombolytic Therapy. 133:110S-112S. 2008
Executive Summary. 133:71S-109S. 2008
Grades of Recommendation for Antithrombotic Agents. 133:123S-131S. 2008
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. 133:257S-298S. 2008
Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development. 133:113S-122S. 2008
New Antithrombotic Drugs. 133:234S-256S. 2008
Parenteral Anticoagulants. 133:141S-159S. 2008
Pharmacology and Management of the Vitamin K Antagonists. 133:160S-198S. 2008
Reflecting on Eight Editions of the American College of Chest Physicians Antithrombotic Guidelines. 133:1293-1295. 2008
The Perioperative Management of Antithrombotic Therapy. 133:299S-339S. 2008
The Primary and Secondary Prevention of Coronary Artery Disease. 133:776S-814S. 2008
Treatment and Prevention of Heparin-Induced Thrombocytopenia. 133:340S-380S. 2008
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy. 133:844S-886S. 2008
Long-Acting Bronchodilators in COPD. 133:1057-1058. 2008
Modifying Track Layout From Straight to Circular Has a Modest Effect on the 6-min Walk Distance. 133:1155-1160. 2008
Point: Evidence-Based Medicine Has a Sound Scientific Base. 133:1067-1071. 2008
Rebuttal From Dr. Guyatt et al. 133:1074-1075. 2008
Development of a Parent-Proxy Quality-of-Life Chronic Cough-Specific Questionnaire. 133:386-395. 2008
Sputum Eosinophils and the Response of Exercise-Induced Bronchoconstriction to Corticosteroid in Asthma. 133:404-411. 2008
So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. 132:1108-1110. 2007
Regulatory T Cells in Allergy and Asthma. 132:1007-1014. 2007
Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. 132:936-945. 2007
Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation. 132:127-134. 2007
Contrast Echocardiography Grading Predicts Pulmonary Arteriovenous Malformations on CT. 132:18-23. 2007
High-Frequency Oscillatory Ventilation for Adult Patients With ARDS. 131:1907-1916. 2007
Who Is (Still) Getting HIT?. 131:1620-1622. 2007
Effects of Nocturnal Noninvasive Mechanical Ventilation on Heart Rate Variability of Patients With Advanced COPD. 131:156-163. 2007
Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin. 131:275-277. 2007
Morbidity and Mortality of Patients With Invasive Group A Streptococcal Infections Admitted to the ICU. 130:1679-1686. 2006
Effect of Rollator Use on Health-Related Quality of Life in Individuals With COPD. 130:1089-1095. 2006
MINIMIZING COSTS FOR TREATING DEEP VEIN THROMBOSIS: THE ROLE FOR FONDAPARINUX. 130:260S-260S. 2006
SYMPTOM CONTROL, PATIENT SATISFACTION, AND TREATMENT COMPLIANCE IN PATIENTS WITH MILD ASTHMA PRESCRIBED LOW-DOSE INHALED CORTICOSTEROIDS. 130:96S-96S. 2006
Gene Therapy for Pulmonary Diseases. 130:879-884. 2006
Montelukast Treatment Attenuates the Increase in Myofibroblasts Following Low-Dose Allergen Challenge. 130:741-753. 2006
The Salmeterol Multicenter Asthma Research Trial. 130:928-928. 2006
Think of HIT When Thrombosis Follows Heparin. 130:631-632. 2006
Staphylococcus aureus in Community-Acquired Pneumonia. 130:623-623. 2006
Understanding Cardiopulmonary Resuscitation Decision Making. 130:419-428. 2006
Cytokines or Their Antagonists for the Treatment of Asthma. 130:244-250. 2006
Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma. 129:1478-1485. 2006
Thrombotic End Point for Assessing Argatroban Therapy for Heparin-Induced Thrombocytopenia. 129:1396-1398. 2006
In Reply: Aerosol Delivery Devices. 129:1389-1389. 2006
Impact of Pulmonary Rehabilitation on Psychosocial Morbidity in Patients With Severe COPD. 129:899-904. 2006
Intensive Care and Emergency Medicine. 129:1061-1067. 2006
Pulmonary Function and Abdominal Adiposity in the General Population. 129:853-862. 2006
The Ontario Asthma Regional Variation Study. 129:909-917. 2006
Treatment Strategy for Asthma. 129:221-223. 2006
Addressing Resource Allocation Issues in Recommendations From Clinical Practice Guideline Panels. 129:182-187. 2006
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines. 129:174-181. 2006
β2 Déjà Vu. 129:3-5. 2006
CARDIO-PULMONARY MEDICAL HISTORY AND THE EFFECT ON CLINICAL OUTCOME OF COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS TREATED WITH GEMIFLOXACIN. 128:372S-372S. 2005
Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism. 128:2203-2210. 2005
Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization. 128:1980-1988. 2005
Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma. 128:1974-1979. 2005
PATIENT RISK FACTORS IN COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS OUTCOME FOLLOWING TREATMENT WITH GEMIFLOXACIN. 128:372S-372S. 2005
THE EFFECT OF DISEASE SEVERITY ON CLINICAL OUTCOME WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS PATIENTS TREATED WITH GEMIFLOXACIN. 128:371S-371S. 2005
A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway. 127:1999-2006. 2005
Dose Capping Enoxaparin Is Unjustified and Denies Patients With Acute Coronary Syndromes a Potentially Effective Treatment. 127:2288-2289. 2005
Warfarin Maintenance Dosing Patterns in Clinical Practice. 127:2049-2056. 2005
Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome. 127:1857-1861. 2005
Lung Volume Reduction Surgery vs Medical Treatment^*. 127:1166-1166. 2005
Asthma in Remission. 127:845-850. 2005
New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. 127:35S-45S. 2005
The Pathophysiology of Heparin-Induced Thrombocytopenia. 127:9S-20S. 2005
Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines. 127:335-371. 2005
Malignant Pleural Mesothelioma. 126:1318-1329. 2004
Plasma D-dimer for Outcome Assessment in Patients With CAP. 126:1015-1016. 2004
Primary Pulmonary Sporotrichosis: A Case Report. 126:945S-945S. 2004
Short-course Gemifloxacin Therapy is Effective Against Streptococcus pneumoniae in a Murine Model of Pneumonia. 126:847S-847S. 2004
Antithrombotic Therapy During Percutaneous Coronary Intervention. 126:576S-599S. 2004
Antithrombotic Therapy for Coronary Artery Disease. 126:513S-548S. 2004
Antithrombotic Therapy in Children*. 126:645S-687S. 2004
Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts. 126:600S-608S. 2004
Antithrombotic and Thrombolytic Therapy: From Evidence to Application. 126:688S-696S. 2004
Applying the Grades of Recommendation for Antithrombotic and Thrombolytic Therapy. 126:179S-187S. 2004
Hemorrhagic Complications of Anticoagulant Treatment. 126:287S-310S. 2004
Heparin and Low-Molecular-Weight Heparin. 126:188S-203S. 2004
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. 126:311S-337S. 2004
Methodology for Guideline Development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy. 126:174S-178S. 2004
New Anticoagulant Drugs. 126:265S-286S. 2004
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. 126:234S-264S. 2004
The Pharmacology and Management of the Vitamin K Antagonists. 126:204S-233S. 2004
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 126:172S-173S. 2004
Use of Antithrombotic Agents During Pregnancy. 126:627S-644S. 2004
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points. 126:501-508. 2004
Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome. 125:1616-1621. 2004
Geographic and Gender Variability in the Prevalence of Bronchial Responsiveness in Canada. 125:1657-1664. 2004
Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia. 125:1888-1901. 2004
Measuring Health-Related Quality of Life in Adults During an Acute Asthma Exacerbation. 125:93-97. 2004
Advances and Contemporary Issues in Prophylaxis for Deep Vein Thrombosis. 124:347S-348S. 2003
Advances and contemporary issues in prophylaxis for deep vein thrombosis.. 124:347S-348S. 2003
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery. 124:379S-385S. 2003
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.. 124:379S-385S. 2003
Temporal Trends in Prevention of Venous Thromboembolism Following Primary Total Hip or Knee Arthroplasty 1996–2001. 124:349S-356S. 2003
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry.. 124:349S-356S. 2003
A Comparison of the Original Chronic Respiratory Questionnaire With a Standardized Version. 124:1421-1429. 2003
Relation Between Lung Function and RBC Distribution Width in a Population-Based Study*. 124:494-500. 2003
A Meta-analysis of Nocturnal Noninvasive Positive Pressure Ventilation in Patients With Stable COPD. 124:337-343. 2003
Dying in the ICU. 124:392-397. 2003
Evaluation of a Practice Guideline for Noninvasive Positive-Pressure Ventilation for Acute Respiratory Failurea. 123:2062-2073. 2003
Short-term Noninvasive Pressure Support Ventilation Prevents ICU Admittance in Patients With Acute Cardiogenic Pulmonary Edemaa. 123:2057-2061. 2003
Airway hyperresponsiveness.. 123:411S-416S. 2003
Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur. 124:371S-371S. 2003
Effects of Nebulized Diethylenetetraamine-NONOate in a Mouse Model of Acute Pseudomonas aeruginosa Pneumonia. 122:2127-2136. 2002
A Randomized Controlled Trial to Evaluate the Effect of Informing Patients About Their Pretreatment Responses to Two Respiratory Questionnaires. 122:1701-1708. 2002
Effect of Air Filtration Systems on Asthma. 122:1535-1542. 2002
The Short-term Effect of a Rollator on Functional Exercise Capacity Among Individuals With Severe COPD. 122:56-65. 2002
Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate. 121:1824-1832. 2002
Safety of Pressure-Volume Curve Measurement in Acute Lung Injury and ARDS Using a Syringe Technique. 121:1595-1601. 2002
The Design of Randomized Clinical Trials in Critically Ill Patients. 121:1290-1300. 2002
Coronary Artery Air Embolism Complicating a CT-Guided Transthoracic Needle Biopsy of the Lung. 121:993-996. 2002
MIASMA. 121:1003-1004. 2002
Airway Hyperresponsiveness and Calcium Handling by Smooth Muscle. 121:621-624. 2002
Discharge Criteria From Perioperative Physical Therapy. 121:488-494. 2002
Evidence-Based Guidelines for Weaning and Discontinuing Ventilatory Support. 120:375S-395S. 2001
Introduction to a Series of Systematic Reviews of Weaning From Mechanical Ventilation. 120:396S-399S. 2001
Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals. 120:454S-463S. 2001
Pharmacoeconomics in Pediatric Asthma. 120:1762-1763. 2001
Predicting Success in Weaning From Mechanical Ventilation. 120:400S-424S. 2001
Qualitative Studies on the Patient's Experience of Weaning From Mechanical Ventilation. 120:469S-473S. 2001
Treatment of Warfarin-Associated Coagulopathy. 120:1972-1976. 2001
Trials Comparing Alternative Weaning Modes and Discontinuation Assessments. 120:425S-437S. 2001
Trials Comparing Early vs Late Extubation Following Cardiovascular Surgery. 120:445S-453S. 2001
Trials of Corticosteroids to Prevent Postextubation Airway Complications. 120:464S-468S. 2001
Trials of Miscellaneous Interventions to Wean From Mechanical Ventilation. 120:438S-444. 2001
Exercise Not Asthma. 120:1434-1435. 2001
Differential Cell Counts in Sputum in Respiratory Epidemiology. 120:1107-1113. 2001
Home Oxygen Requalification. 120:318-319. 2001
Do Blood Transfusions Improve Outcomes Related to Mechanical Ventilation?. 119:1850-1857. 2001
Deleterious Effects of Inhaled β-Agonists. 119:1297-1299. 2001
Sleep in critically ill patients requiring mechanical ventilation (vol. 117, pg 809, 2000). 119:993-993. 2001
Marked Tachypnea in Siblings With Chronic Beryllium Disease due to Copper-Beryllium Alloy. 119:647-650. 2001
Nutritional Intervention in COPD. 119:353-363. 2001
A Qualitative Systematic Overview of the Measurement Properties of Functional Walk Tests Used in the Cardiorespiratory Domain. 119:256-270. 2001
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. 119:321S-336S. 2001
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. 119:220S-227S. 2001
Antithrombotic therapy in patients undergoing percutaneous coronary intervention. 119:321S-336S. 2001
Grades of Recommendation for Antithrombotic Agents. 119:3S-7S. 2001
Hemorrhagic Complications of Anticoagulant Treatment. 119:108S-121S. 2001
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. 119:64S-94S. 2001
Left Ventricular Wall Stress During Leg-Press Exercise Performed With a Brief Valsalva Maneuver. 119:150-154. 2001
Managing Oral Anticoagulant Therapy. 119:22S-38S. 2001
Managing oral anticoagulant therapy.. 119:22S-38S. 2001
New Anticoagulant Drugs. 119:95S-107S. 2001
New anticoagulant drugs. 119:95S-107S. 2001
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. 119:8S-21S. 2001
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.. 119:8S-21S. 2001
Platelet-Active Drugs. 119:39S-63S. 2001
Platelet-active drugs : the relationships among dose, effectiveness, and side effects.. 119:39S-63S. 2001
The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for Prevention and Treatment of Thrombosis. 119:1S-2S. 2001
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians.. 119:1S-2S. 2001
Use of Antithrombotic Agents During Pregnancy. 119:122S-131S. 2001
Use of antithrombotic agents during pregnancy.. 119:122S-131S. 2001
Appropriateness of Domiciliary Oxygen Delivery. 118:1303-1308. 2000
Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure. 118:914-922. 2000
Dissecting Aortic Aneurysm. 118:880-880. 2000
Pulmonary Function Is a Long-term Predictor of Mortality in the General Population. 118:656-664. 2000
Acute Airway Obstruction Secondary to Bilateral Broncholithiasis. 117:1205-1207. 2000
Endotracheal Aspiration in the Diagnosis of Ventilator-Associated Pneumonia. 117:195S-197S. 2000
Long-term Effects of Outpatient Rehabilitation of COPD. 117:976-983. 2000
Nutritional Support for Individuals With COPD. 117:672-678. 2000
Sleep in Critically Ill Patients Requiring Mechanical Ventilation. 117:809-818. 2000
Health-Related Quality of Life in Moderate Asthma. 116:1297-1303. 1999
Physician Preferences for Perioperative Anticoagulation in Patients With a Mechanical Heart Valve Who Are Undergoing Elective Noncardiac Surgery. 116:1240-1246. 1999
Trends in the Epidemiology of COPD in Canada, 1980 to 1995. 116:306-313. 1999
Heparin and low-molecular-weight heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety (vol 114, pg 495S, 1998). 115:1760-1760. 1999
A Randomized Controlled Trial on the Effect of Inhaled Corticosteroids on Airways Inflammation in Adult Cigarette Smokers. 115:1271-1277. 1999
Validation of a Standardized Version of the Asthma Quality of Life Questionnaire. 115:1265-1270. 1999
The Clinical Utility of Invasive Diagnostic Techniques in the Setting of Ventilator-Associated Pneumonia. 115:1076-1084. 1999
Exogenous lipid pneumonia related to smoking "weed oil" in association with pulmonary alveolar proteinosis post cadaveric renal transplantation. 116:427. 1999
Percutaneous tracheostomy: is it really better?. 114:1771-1772. 1998
Reversal of the Anticoagulant Effects of Warfarin by Vitamin K1. 114:1505-1508. 1998
Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. 114:728S-741S. 1998
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. 114:602S-610S. 1998
Antithrombotic therapy in patients undergoing coronary angioplasty. 114:728S-741S. 1998
Grades of Recommendation for Antithrombotic Agents. 114:441S-444S. 1998
Hemorrhagic Complications of Anticoagulant Treatment. 114:511S-523S. 1998
Heparin and Low-Molecular-Weight Heparin. 114:489S-510S. 1998
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.. 114:489S-510S. 1998
New Antithrombotic Agents. 114:715S-727S. 1998
New antithrombotic agents. 114:715S-727S. 1998
Oral Anticoagulants. 114:445S-469S. 1998
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.. 114:445S-469S. 1998
Platelet-active drugs: the relationships among dose, effectiveness, and side effects.. 114:470S-488S. 1998
Use of Antithrombotic Agents During Pregnancy. 114:524S-530S. 1998
Use of antithrombotic agents during pregnancy.. 114:524S-530S. 1998
Intratracheal Pulmonary Ventilation at Low Airway Pressures in a Ventilator-Induced Model of Acute Respiratory Failure Improves Lung Function and Survival. 114:1147-1157. 1998
The Effect of Positive Pressure Airway Support on Mortality and the Need for Intubation in Cardiogenic Pulmonary Edema. 114:1185-1192. 1998
Evidence for the Needs of Out-of-Hospital Thrombosis Prophylaxis. 114:113S-114S. 1998
Managing Cough as a Defense Mechanism and as a Symptom. 114:133S-181S. 1998
The Incidence of Symptomatic Venous Thromboembolism After Enoxaparin Prophylaxis in Lower Extremity Arthroplasty. 114:115S-118S. 1998
The Timing of Tracheotomy. 114:605-609. 1998
Is It ‘Worthwhile' To Continue Treating Patients With a Prolonged Stay (>14 Days) in the ICU?. 114:192-198. 1998
Is There Really A Controversy Surrounding the Effectiveness of Respiratory Rehabilitation in COPD?. 114:1-4. 1998
The Influence of 6 Months of Oral Anabolic Steroids on Body Mass and Respiratory Muscles in Undernourished COPD Patients. 114:19-28. 1998
Nosocomial Pneumonia Guidelines. 113:188S-193S. 1998
Benefit of Heparin in Central Venous and Pulmonary Artery Catheters. 113:165-171. 1998
Intratracheal Pulmonary Ventilation and Continuous Positive Airway Pressure in a Sheep Model of Severe Acute Respiratory Failure. 112:1060-1067. 1997
A New Index of Prognostic Severity for Chronic Asthma. 112:582-590. 1997
Respiratory Failure Following Vinorelbine Tartrate Infusion in a Patient With Non-small Cell Lung Cancer. 112:846-848. 1997
Economic Analysis of Respiratory Rehabilitation. 112:370-379. 1997
Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung.. 111:137S. 1997
In vivo adenovirus-mediated expression of human pre-elafin, a potent neutrophil elastase inhibitor.. 111:128S-129S. 1997
Transient Gene Transfer and Expression in the Lung. 111:89S-94S. 1997
The Components of a Respiratory Rehabilitation Program. 111:1077-1088. 1997
Introduction. 111:1S-1S. 1997
Leukotrienes in the Pathogenesis of Asthma. 111:27S-34S. 1997
Mycobacterium avium Complex Infection in an Immunocompetent Young Adult Related to Hot Tub Exposure. 111:242-245. 1997
Symptom Intensity and Subjective Limitation to Exercise in Patients With Cardiorespiratory Disorders. 110:1255-1263. 1996
Asthma quality of life survey. 110:81. 1996
Misunderstanding and misuse: Canadian asthmatics' patterns of use and knowledge of Inhaled Steroids (IS). 110:132. 1996
Quality of Life (QOL) of Canadian asthma sufferers. 110:132. 1996
Risk factors for breakthrough PCP in HIV-infected patients receiving aerosol pentamidine. 110:70. 1996
An Effectiveness Community-Based Clinical Trial of Respirgard II and Fisoneb Nebulizers for Pneumocystis carinii Prophylaxis With Aerosol Pentamidine in HIV-Infected Individuals. 110:141-146. 1996
Long-acting β-Agonists, Tachyphylaxis, and Corticosteroids. 109:862-864. 1996
Pulmonary Embolism With Duplicated Inferior Vena Cava. 109:1111-1113. 1996
Metered-Dose Inhaler Salbutamol-Induced Tracheal Epithelial Lesions in Intubated Rabbits. 108:1668-1672. 1995
Antithrombotic Therapy for Cerebrovascular Disorders. 108:444S-456S. 1995
Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. 108:486S-501S. 1995
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. 108:371S-379S. 1995
Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts. 108:424S-430S. 1995
Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects.. 108:247S-257S. 1995
Clinical Recommendations Using Levels of Evidence for Antithrombotic Agents. 108:227S-230S. 1995
Hemorrhagic Complications of Anticoagulant Treatment. 108:276S-290S. 1995
Hemorrhagic complications of anticoagulant treatment.. 108:276S-290S. 1995
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism.. 108:291S-301S. 1995
Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. 108:258S-275S. 1995
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.. 108:258S-275S. 1995
New Antithrombotics. 108:471S-485S. 1995
Oral Anticoagulants. 108:231S-246S. 1995
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.. 108:231S-246S. 1995
Prevention of Venous Thromboembolism. 108:312S-334S. 1995
Community-Acquired Pneumonia. 108:35S-42S. 1995
Regular β-Adrenergic Agonists. 108:589-590. 1995
Regular β-Adrenergic Agonists-To the Editor. 108:590-590. 1995
Interobserver Variation in the Computed Tomographic Evaluation of Mediastinal Lymph Node Size in Patients With Potentially Resectable Lung Cancer. 107:116-119. 1995
Occupational Exposure and Pulmonary Function in Health Care Workers in an Aerosol Pentamidine Clinic. 106:980-981. 1994
Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis. 106:718-724. 1994
Mirror-image tumors in mirror-image twins.. 106:608-610. 1994
Regular Beta-Adrenergic Agonists. 106:552-559. 1994
Dose-effect Relationship of the β-Agonists Fenoterol and Salbutamol in Patients With Asthma. 105:1738-1742. 1994
Mortality Risk and Patterns of Practice in 2,070 Patients With Acute Myocardial Infarction, 1987-92. 105:1687-1692. 1994
Oral Anticoagulants-To the Editor. 105:1903-1903. 1994
Dosing Efficiency and Particle-Size Characteristics of Pressurized Metered-Dose Inhaler Aerosols in Narrow Catheters. 105:1621-1622. 1994
Effect of Magnitude of Airway Responsiveness and Therapy With Inhaled Corticosteroid on Histamine Tachyphylaxis in Asthma. 105:1434-1438. 1994
Selective Decontamination of the Digestive Tract. 105:1221-1229. 1994
Prevention and Regression of Coronary Atherosclerosis. 105:718-726. 1994
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents. 105:647-647. 1994
Efficiency of Bronchodilator Aerosol Delivery to the Lungs From the Metered Dose Inhaler in Mechanically Ventilated Patients. 105:214-218. 1994
Oral Anticoagulant Therapy Recommendations. 105:328-328. 1994
D-Dimer in Patients With Clinically Suspected Pulmonary Embolism. 104:1679-1684. 1993
β-Agonists and Bronchial Asthma. 104:652-653. 1993
A Placebo-controlled Dose-finding Study With Bambuterol in Elderly Patients With Asthma. 103:771-776. 1993
Dosing Efficiency and Particle-size Characteristics of Pressurized Metered-dose Inhaler Aerosols in Narrow Catheters. 103:920-924. 1993
Exposure of Health-Care Workers to Aerosolized Pentamidine. 103:982-983. 1993
Treatment of Community-acquired Pneumonia. 103:697-701. 1993
Concurrent Catamenial Hemothorax and Hemopneumothorax. 103:646-648. 1993
Management of Metastatic Non-Small-Cell Lung Cancer and a Consideration of Cost. 103:68S-71S. 1993
Management of metastatic non-small-cell lung cancer and a consideration of cost. 103:68S-71. 1993
Increased Inhaled Bronchodilator vs Increased Inhaled Corticosteroid in the Control of Moderate Asthma. 102:1709-1715. 1992
Skeletal Muscle Metabolism in the Chronic Fatigue Syndrome. 102:1716-1722. 1992
Antithrombotic Agents in Coronary Artery Disease. 102:456S-481S. 1992
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. 102:445S-455S. 1992
Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts Following Percutaneous Transluminal Coronary Angioplasty. 102:508S-515S. 1992
Antithrombotic therapy. Introduction.. 102:303S-304S. 1992
Aspirin and Other Platelet-Active Drugs. 102:327S-336S. 1992
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.. 102:327S-336S. 1992
Cardiac Output Determination during Progressive Exercise in Cystic Fibrosis. 102:1118-1123. 1992
Hemorrhagic Complications of Anticoagulant Treatment. 102:352S-363S. 1992
Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism. 102:364S-373S. 1992
Hemorrhagic complications of anticoagulant treatment.. 102:352S-363S. 1992
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism.. 102:364S-373S. 1992
Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. 102:337S-351S. 1992
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.. 102:337S-351S. 1992
Oral Anticoagulants. 102:312S-326S. 1992
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. 102:312S-326. 1992
Prevention of Venous Thromboembolism. 102:391S-407S. 1992
RULES OF EVIDENCE AND CLINICAL RECOMMENDATIONS ON THE USE OF ANTITHROMBOTIC AGENTS. 102:S305-S311. 1992
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents. 102:305S-311S. 1992
Use of Antithrombotic Agents During Pregnancy. 102:385S-390S. 1992
Use of antithrombotic agents during pregnancy.. 102:385S-390S. 1992
Ciliary Function, Cell Viability, and in Vitro Effect of Ribavirin on Nasal Epithelial Cells in Acute Rhinorrhea. 102:284-287. 1992
The Clinical Utility of Postinfarction Risk Prediction. 101:534-540. 1992
Gastric Colonization by Gram-Negative Bacilli and Nosocomial Pneumonia in the Intensive Care Unit Patient. 101:187-193. 1992
Nosocomial Pneumonia and the Role of Gastric pH. 100:7-13. 1991
Randomized Trials to Assess the Long-term Effects of Therapies on Angiographic End Points. 99:1243-1247. 1991
Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.. 99:128S-128S. 1991
Allergistis non Carborundum. 99:522-522. 1991
A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism. 98:1473-1479. 1990
Clinical Dysautonomia in Patients with Bronchial Asthma. 98:1408-1413. 1990
Recidivism Revisited. 98:790-791. 1990
A NEW SHORT INFUSION DOSAGE REGIMEN OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE. 97:S168-S171. 1990
A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease. 97:168S-171S. 1990
Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis. 97:172S-175S. 1990
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.. 97:172S-175S. 1990
Accuracy of Asthma Mortality in France. 97:508-509. 1990
Clinical Validity of a Normal Perfusion Lung Scan in Patients with Suspected Pulmonary Embolism. 97:23-26. 1990
ADJUVANT THERAPY FOR NON-SMALL CELL LUNG-CANCER. 96:S87-S91. 1989
Adjuvant therapy for non-small cell lung cancer.. 96:87S-91S. 1989
The Cardiopulmonary and Renal Hemodynamic Effects of Norepinephrine in Canine Pulmonary Embolism. 95:1333-1337. 1989
Pulmonary Infiltration with Blood Eosinophilia after Scorpion Sting. 95:691-692. 1989
Stump Neuroma Masquerading as Recurrent Malignancy on Chest Roentgenogram. 95:684-685. 1989
ASPIRIN AND OTHER PLATELET ACTIVE-DRUGS - RELATIONSHIP AMONG DOSE, EFFECTIVENESS, AND SIDE-EFFECTS. 95:S12-S18. 1989
Antithrombotic Agents in Coronary Artery Disease. 95:52S-72S. 1989
Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects. 95:12S-18. 1989
HEMORRHAGIC COMPLICATIONS OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL-INFARCTION AND VENOUS THROMBOEMBOLISM. 95:S88-S97. 1989
Hemorrhagic Complications of Long-term Anticoagulant Therapy. 95:26S-36S. 1989
Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism. 95:88S-97S. 1989
Hemorrhagic complications of long-term anticoagulant therapy.. 95:26S-36S. 1989
Optimal Therapeutic Range for Oral Anticoagulants. 95:5S-11S. 1989
Optimal therapeutic range for oral anticoagulants [published erratum appears in Chest 1989 Oct;96(4):962]. 95:5S-11. 1989
Optimal therapeutic range for oral anticoagulants.. 95:5S-11S. 1989
Use of Anticoagulants during Pregnancy. 95:156S-160S. 1989
Use of anticoagulants during pregnancy.. 95:156S-160S. 1989
International Trends in Asthma Mortality: 1970 to 1985. 94:914-918. 1988
Aspergillus terreus as a Cause of Invasive Pulmonary Aspergillosis. 94:889-891. 1988
Comparison of the Effects of Nebulized Terbutaline with Intravenous Enprofylline in Patients with Acute Asthma. 93:510-514. 1988
The Diagnosis and Management of Supraventricular Tachycardia by Transesophageal Cardiac Stimulation and Recording. 93:339-344. 1988
Cardiovascular Effects of Smoking in Patients with Ischemic Heart Disease. 93:14-19. 1988
THE USE OF BETA-ADRENERGIC BLOCKING-AGENTS, IV NITRATES AND CALCIUM-CHANNEL BLOCKING-AGENTS FOLLOWING ACUTE MYOCARDIAL-INFARCTION. 93:S25-S28. 1988
The Use of Beta-adrenergic Blocking Agents, IV Nitrates and Calcium Channel Blocking Agents following Acute Myocardial Infarction. 93:25S-28S. 1988
Measurement of Cardiac Output by CO2 Rebreathing in Unsteady State Exercise. 92:777-782. 1987
A Controlled Trial of Ambroxol in Chronic Bronchitis. 92:618-620. 1987
Rigorous Evaluation. 92:580-581. 1987
Aerosol Therapy: Nebulizer vs Metered Dose Inhaler. 91:799-800. 1987
Aerosol Therapy of Reversible Airflow Obstruction Concepts and Clinical Applications. 91:58s-64s. 1987
Airway Inflammation and Airway Hyperresponsiveness. 90:575-577. 1986
A Meta-analysis of the Studies of Dihydroergotamine plus Heparin in the Prophylaxis of Deep Vein Thrombosis. 89:396S-400S. 1986
Introduction. 89:369S-369S. 1986
Prophylaxis of Venous Thromboembolism. 89:374S-383S. 1986
Prophylaxis of venous thromboembolism. An overview.. 89:374S-383S. 1986
TREATMENT OF VENOUS THROMBOEMBOLISM. 89:S426-S433. 1986
Treatment of Venous Thromboembolism. 89:426S-433S. 1986
Venous Thromboembolism. 89:370S-373S. 1986
Venous thromboembolism. Scope of the problem. 89:370S-373. 1986
Optimal Use of MDIs. 89:469-469. 1986
"Therapeutic range" for oral anticoagulant therapy.. 89:11S-15S. 1986
Antithrombotic Agents in Coronary Artery Disease. 89:54S-67S. 1986
Dose Antiplatelet Agents; The Relationship Among Side Effects, and Antithrombotic Effectiveness. 89:4S-10S. 1986
Hemorrhagic Complications of Long-term Anticoagulant Therapy. 89:16S-25S. 1986
Hemorrhagic complications of long-term anticoagulant therapy.. 89:16S-25S. 1986
“Therapeutic Range” for Oral Anticoagulant Therapy. 89:11S-15S. 1986
Diagnostic Value of Ventilation-Perfusion Lung Scanning in Patients with Suspected Pulmonary Embolism. 88:819-828. 1985
Hemodynamic and Myocardial Metabolic Consequences of PEEP. 88:496-502. 1985
Isoxsuprine and Pulmonary Edema. 88:643-644. 1985
Are Active and Passive Smoking Harmful?. 88:445-451. 1985
The Objective Measurement of Breathlessness. 88:84S-90S. 1985
Inhalation Challenge Tests and Airway Responsiveness in Man. 87:202S-206S. 1985
Advances in the Use of Inhalation Provocation Tests in Clinical Evaluation. 87:32S-35S. 1985
Inhalation challenge tests and airway responsiveness in man. 87:2025-2055. 1985
Sotalol Infusion in the Treatment of Supraventricular Tachyarrhythmias. 87:113-118. 1985
Noninvasive Measurement of Mixed Venous Pco 2. 85:449-450. 1984
Clinical Evaluation of a Simple Demand Inhalation MDI Aerosol Delivery Device. 84:36-41. 1983
The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients. 80:904-907. 1981
The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients.. 80:904-907. 1981
OPTIMAL DELIVERY OF AEROSOLS FROM METERED DOSE INHALERS. 80:911-915. 1981
THE DYSKINETIC CILIA SYNDROME - ABNORMAL CILIARY MOTILITY IN ASSOCIATION WITH ABNORMAL CILIARY ULTRASTRUCTURE. 80:860-864. 1981
What's in Exercise?. 78:678-679. 1980
The Dyskinetic Cilia Syndrome. 78:580-582. 1980
Chlorpromazine and Dopamine in Shock. 74:319-319. 1978
Aerosol Therapy with Sch 1000. 73:501-506. 1978
Measurements of Cardiac Output in Seriously Ill Patients Using a CO2 Rebreathing Method. 73:167-172. 1978
Use of Exercise in Testing Respiratory Control Mechanisms. 70:169-173. 1976
Restoration of Regional Wall Motion by Nitroglycerin Therapy in Patients with Left Ventricular Asynergy. 66:545-548. 1974

Chest Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)